Against the high-stakes backdrop of the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco in January 2026, OnDosis CEO Martin Olovsson reveals how a decade of rigorous preparation and an "iPad-style" approach to precision dosing are paving the way for a major U.S. launch.

What does it mean to lead with purpose in life science? We sat down with Johanna Bergh, Business Area Manager for Life Science at AWA, to talk about intellectual property, global collaboration, and why supporting initiatives like the Swedish–African Neurosurgical Collaboration creates impact that lasts.

How do you build trust in a sector where progress takes years? Helena Strigård (Ventures Accelerated) shares key insights and explores the critical balance between transparency, risk, and long-term potential in early-stage life science investing.

From Southern California to Seattle, Ventures  Accelerated is set on a fast-paced expansion as they are establishing footholds in every major life science hub of the U.S. West Coast while appointing Roger Lias, Ph.D. as President of  its U.S. operations.

With roots in journalism at Reuters News in Hong Kong and a career spanning global health, biotech, and nonprofit advocacy, Alexandra Hoegberg is a master of message and mission. Her strategic communications work has influenced policy, built reputations, and connected stakeholders across borders and sectors. She is now a fierce entrepreneur and consultant – and recently joined the Ventures Accelerated team. 

Founder Helena Strigård interviews her on the driving force behind that sharp pen of hers! 

JPM Healthcare Week is no longer about being seen: it’s about being ready. In this piece, conversations with OnDosis and Treos Bio reveal how strategic clarity, credible data, and execution maturity now define meaningful engagement at JPM. From personalized drug delivery to globally aligned clinical development, the article highlights what it takes to show up with intent in today’s capital-constrained market.

In this Corporate Insights, Julie Ames, President and CEO of The Cambridge Group, argues that JP Morgan Healthcare Week is not about visibility, but reputation. Drawing on deep experience advising life science leaders, she explains how JPM has become a high-signal stress test where strategic clarity, disciplined storytelling, and leadership judgment matter more than volume or hype. The piece outlines how companies are evaluated before, during, and after the week, and why those that arrive prepared build momentum long after JPM ends.

As the global life science community gathers for JPM Healthcare Conference Week, attention turns to where capital will flow next. Drawing on a recent Economist analysis, Anders Månsson examines Stockholm’s emergence as a European “capital of capital” — driven by stability, proximity between science and finance, and an innovation-led growth model.

Meet Tracy Humphries, one of our Accelerators, who shares her perspective on the evolving B2B buyer journey. Drawing on 25+ years in life sciences, she discusses why trust, lifecycle marketing, and close alignment between marketing and sales are essential for engaging customers in a digital and AI-driven world.

At a panel discussion organized by EY Parthenon, investors and industry leaders examined the tightening funding landscape for early-stage Nordic life science companies. The message was clear: strong science alone is no longer enough. Success now requires strategic clarity, disciplined execution, early investor engagement, and partnerships that build credibility in a more selective market.

Busyness creates motion, but impact requires direction. In this editorial, Anders Månsson challenges the culture of constant activity and argues for a sharper focus on judgment, clarity, and purposeful leadership. Because real results come from what truly matters, not from doing more.

One of our Accelerators, Rebeca Varela Lores, shares her journey from biomedical sciences to bioentrepreneurship and how her international experiences have shaped a global outlook on innovation. Now part of the Ventures Accelerated team, Rebeca reflects on lessons from early-stage ventures, the excitement of working at the intersection of science and strategy, and the mindset needed to turn bold ideas into impact.